Home MarketAlkem Laboratories Ltd.

Alkem Laboratories Ltd. Stock Info: As on 2018-02-20 12:53:05

Nse

2178.50

19.85(0.92%)
Change%
52 Week Range
1,578.30
11.00
2,469.00
10.00
Open2,158.65
Day's Range1,726.92 - 2,590.38
Value Traded (in ₹ Cr.) 1.89

Bse

2174.95

4.35(0.20%)
Change %
52 Week Range
1,578.00
11.00
2,468.00
10.00
Open2,149.00
Day's Range1,736.48 - 2,604.72
Value Traded (in ₹ Cr.) 0.24

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 78,743,120.00 65.86%
Mutual Funds/UTI 2,851,716.00 2.39%
FII 4,727,533.00 3.95%
Employee 0.00 0.00%
Public 30,509,013.00 25.52%
Government 0.00 0.00%
Others 2,429,088.00 2.03%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 4.16
Basic EPS (Rs.) 53.40
Cash EPS 59.55
BVPerShare Excl 297.51
Operating Revenue 328.29
PBDITPerShare 73.01
Dividend 12.70
NPPerShare 53.40
Current Ratio 1.74
Quick Ratio 1.23
PriceToBV 4.59
Earnings 0.03
PBDIT Margin 22.23
PBT Margin 19.00
NP Margin 16.26
Return On Assets 13.15
Retention Ratios 76.21
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 4,085.21
Total Expenses 3,339.25
EBITDA 872.79
PBT 745.96
PAT 638.44
Net Income 638.44
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,932.73
Total Expenses 1,580.55
EBITDA 316.31
PBT 332.13
PAT 227.59
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 23.91
Net worth 3,556.70
Investments 1,071.13
Total Liability 4,853.33
Total debt 350.62
Net block 1,021.24
Total Assets 4,853.33
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 23.91
Net worth 3,472.04
Investments 1,063.05
Total Liability 5,118.18
Total debt 872.21
Net block 987.26
Total Assets 5,118.18
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

629.95 624.05 0.95
616.55680

Abbott India Ltd.

5650.05 5686.15 -0.63
5470.056125

Ajanta Pharma Ltd.

1336.95 1350.35 -0.99
1321.51438

Albert David Ltd.

371.5 371 0.13
370.05410.85

Alembic Ltd.

60.8 60.6 0.33
60.3564.4

Alembic Pharmaceuticals Ltd.

571.9 554.8 3.08
546.8589.4

Alpa Laboratories Ltd.

42.3 43.35 -2.42
40.6546.6
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

50 51.25 -2.44
50.157.55

Aarti Drugs Ltd.

633.7 626.9 1.08
620680

Aayush Food & Herbs Ltd.

64.95 64.4 0.85
59.177.3

Abbott India Ltd.

5675.15 5667.4 0.14
55006059.2

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 629.81
Cash from investing activities 310.84
Cash from financing activities -958.16
Net change in cash -17.48

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal MOSt Focused Multicap 35 Fund 2.03%
DSP BlackRock Small And Mid Cap Fund 1.73%
Reliance Growth Fund 1.23%
SBI Pharma Fund 5.83%
DSP BlackRock Balanced Fund 0.90%
DSP BlackRock Opportunities Fund 1.15%

Sebi revokes curbs on Sanco Industries

Markets regulator Sebi has lifted the curbs imposed on Sanco Industries, which was among the suspected shell companies, after finding no prima facie evidence of misrepresentation of financials by the company. ...I do not find any prima facie evidence nor suspicion of misrepresentation of financials/ business by the company (Sanco Industries), misuse of books of accounts/ funds of the company or violation of LODR (Listing Obligations and Disclosure Requirements) Regulations, Sebi Whole Time Member Madhabi Puri Buch said in an order dated February 15. Buch also said that she is of the considered view that the actions envisaged in Sebi's letter dated August 7, 2017 against Sanco Industries are liable to be revoked. Sanco Industries was among the firms against whom the Securities and Exchange Board of India (Sebi) initiated action on August 7 by ordering trading restrictions, following receipt of a list of 331 'suspected shell companies' from the government. The ordered trade restrictions - allowing trade only once a month and that too for only buy transactions with a 200 per cent security deposit - were revoked in some cases a few days later following appeals filed by them with the Securities Appellate Tribunal, but Sebi was asked to continue with its probe and pass its orders expeditiously.

20-02-2018 10:04

Promoter buys stake worth Rs 111 cr in KEC Intl

KEC International's promoter Instant Holdings today bought over 1 per cent stake in the infrastructure major for Rs 111 crore through an open market transaction. According to the block deal data available with the BSE, the promoter purchased 28.05 lakh shares, amounting to 1.09 per cent stake in the firm. The shares were acquired at an average price of Rs 395.95, valuing the transaction at Rs 111.07 crore, the data showed. At the end of the December 2017 quarter, Instant Holdings held 1.80 crore shares, or 7.01 per cent, in KEC International. The shares were sold by Stellar Energy Trust. In a separate block deal, Instant Holdings disposed of 14.81 per cent stake in the drug firm RPG Life Sciences for Rs 110.94 crore. The data showed that Instant Holdings, a promoter of RPG Life Sciences, offloaded 24.50 lakh shares, or 14.81 per cent, in the drug firm. The shares were sold at a price of Rs 452.85 apiece, translating into a transaction worth Rs 110.94 crore. Instant Holdings controlled 16.53 per cent stake in RPG Life Sciences at the end of December 2017 quarter. The shares were purchased by Nucleus Life Trust. Meanwhile, shares of the company were trading at Rs 384.45 apiece, up 2.11 per cent from the previous close at 10:11 hours on BSE.

20-02-2018 10:04

Prime Focus’ arm bags award for Best Special Visual Effects

Prime Focus has said that its arm Double Negative (DNEG) has been honoured at the BAFTA awards 2018 for its work on ‘Blade Runner 2049’. The film picked up the award for ‘ Best Special Visual Effects ’ at the star - studded ceremony last night. This is the third award that DNEG has won in less than a week , having picked up two Visual Effects Society awards last Tuesday for its work on Denis Villeneuve’s ‘Blade Runner 2049’ and Christopher Nolan’s ‘Dunkirk’. DNEG was the lead Visual Effects house for both films , and is also nominated in the ‘ Best Visual Effects’ category for its work on ‘Blade Runner 2049’ at the 90th Academy Awards on March 4th 2018 in Los Angeles. Led by VFX Supervisor Paul Lambert, DNEG’s Blade Runner team delivered most of the Los Angeles 2049 cityscapes, the Joi hologram effects and the seawall chase at the end of the movie. Meanwhile, shares of the company closed at Rs 101.15 apiece, down 1.27 per cent from the previous close at 10:03 hrs on BSE.

20-02-2018 10:03

IndiGrid completes acquisition of three assets

IndiGrid has said that it has completed the acquisition of three assets - RAPP Transmission Company Limited, Purulia and Kharagpur Transmission Company Limited and Maheshwaram Transmission Limited from its Sponsor- Sterlite Power Grid Ventures Limited . It has simultaneously signed definitive agreements with Techno Electric & Engineering Company Limited to invest in Patran Transmission Company Limited (“PTCL”). The purchase consideration for MRP is INR 14.10 billion and for PTCL is INR 2.32 billion. Both these acquisitions are highly accretive and will increase portfolio IRR to 11% at current price. They will enable IndiGrid to deliver a DPU of at least INR 12 for the next five years . Commenting on the developments, Pratik Agarwal, Chief Executive Officer, IndiGrid , said, “ In line with its vision of reaching an AUM of INR 300 billion, IndiGrid has successfully completed the first set of the acquisition s. Further, we have demonstrated our ability to pursue third party assets by signing definitive agreement s with Techno Electric . The fundamentals of the power transmission sector in India remain robust and IndiGrid will continue to acquire assets from both the Sponsor and third parties to further increase portfolio IRR ” .

20-02-2018 10:00

NTPC pays interim dividend of Rs 2,251 cr to shareholders

State-run power giant NTPC today said it has paid interim dividend of Rs 2,251 crore for 2017-18. For the financial year 2017-18, NTPC Ltd has paid an interim dividend of Rs 2,251.01 crore,being 27.30 per cent of the paid-up equity share capital of the company, an NTPC Ltd statement said. According to the statement, the real-time gross settlement advice for the transfer of Rs 1,401.81 crore, to the Government of India, being its share in the interim dividend, was presented by NTPC CMD Gurdeep Singh to R K Singh, Minister of State for Power and New and Renewable Energy.This is the 25th consecutive year that NTPC has paid dividend, it added. Meanwhile, shares of the company were trading at Rs 163.45 apiece, up 0.28 per cent from the previous close at 10:06 hours on BSE.

20-02-2018 09:57

Alkem Laboratories Q3 net profit down 0.35% at Rs 212.97 cr

The company reported standalone net profit of Rs 212.97 crore for the quarter ended December 31, 2017 as compared to Rs 213.71 crore in the same period last year, registering a year-on-year decline of 0.35 per cent. Net revenue of the company rose substantially by 24.68 per cent at Rs 1,422.52 crore in October-December quarter of this fiscal as against Rs 1,140.94 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 17.98 per cent to Rs 1,109.05 crore from Rs 940.00 crore in year ago period. Other Income dipped by 1.86 per cent at Rs 22.69 crore versus (Dec'16 Rs 23.12 crore). Operating Profit surged by 42.08 per cent to Rs 313.47 crore as against Rs 220.63 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 13.96 per cent in December quarter. Interest grew by 8.13 per cent y-o-y to Rs 7.18 crore, while Taxation increased by 2289.92 per cent at Rs 87.71 crore (Dec'16 Rs 3.67 crore).

09-Feb-2018 02:51 PM

Alkem Laboratories - Board Meeting-Closure of Trading Window

Intimation of Opening of Trading Window

We refer to our earlier communication dated 26th December, 2017 regarding closure of trading window (for the purpose of financial results for the quarter and nine months ended 31st December, 2017) starting from 30th December, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended 31st December, 2017 are communicated to the Stock Exchanges.

The Financial Results of the Company for the quarter and nine months ended 31st December, 2017 having been communicated to the Stock Exchanges, today i.e. 9th February, 2018, the trading window shall open on 12th February, 2018

09-Feb-2018 02:22 PM

Alkem Laboratories - Trading Window

Alkem Laboratories Limited has informed the Exchange regarding Intimation of Opening of Trading Window.

09-Feb-2018 02:14 PM

Alkem Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q3FY18 and 9MFY18 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take note of the same.

09-Feb-2018 02:07 PM

Alkem Laboratories - Corporate Action-Board approves Dividend

The Board of Directors of the Company, at its meeting held today, i.e. 9th February, 2018 inter alia, has Declared Interim Dividend of Rs. 6/- (Rupees Six only) per equity share on the face value of Rs. 2/- per share for the financial year 2017-18 pursuant to Regulation 43 read with Regulation 30 of the Listing Regulations.

The date of payment of Interim Dividend shall be on and from 23rd February, 2018.

Further, as informed vide our letter dated 31st January, 2018 submitted to the Stock Exchanges pursuant to Clause 42 of the Listing Regulations, the record date for the purpose of payment of interim dividend for the financial year 2017-18 would be Tuesday, 20th February, 2018.

09-Feb-2018 02:02 PM

Alkem Laboratories - Board Meeting-Closure of Trading Window

Intimation of Opening of Trading Window

We refer to our earlier communication dated 26th December, 2017 regarding closure of trading window (for the purpose of financial results for the quarter and nine months ended 31st December, 2017) starting from 30th December, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended 31st December, 2017 are communicated to the Stock Exchanges.

The Financial Results of the Company for the quarter and nine months ended 31st December, 2017 having been communicated to the Stock Exchanges, today i.e. 9th February, 2018, the trading window shall open on 12th February, 2018

09-Feb-2018 02:22 PM

Alkem Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q3FY18 and 9MFY18 earnings and business updates and the same will be uploaded on the website of the Company.

Kindly take note of the same.

09-Feb-2018 02:07 PM

Alkem Laboratories - Corporate Action-Board approves Dividend

The Board of Directors of the Company, at its meeting held today, i.e. 9th February, 2018 inter alia, has Declared Interim Dividend of Rs. 6/- (Rupees Six only) per equity share on the face value of Rs. 2/- per share for the financial year 2017-18 pursuant to Regulation 43 read with Regulation 30 of the Listing Regulations.

The date of payment of Interim Dividend shall be on and from 23rd February, 2018.

Further, as informed vide our letter dated 31st January, 2018 submitted to the Stock Exchanges pursuant to Clause 42 of the Listing Regulations, the record date for the purpose of payment of interim dividend for the financial year 2017-18 would be Tuesday, 20th February, 2018.

09-Feb-2018 02:02 PM

Corporate Details

About Management

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility

Registered Office

MIDC, Taloja

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.